SunWay Biotech Co., LTD. (TPEX: 1271)
90.00
+0.10 (0.11%)
Sep 10, 2024, 1:14 PM CST
SunWay Biotech Co., LTD. Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 99.6 | 44.08 | 30.04 | 168.76 | 125.71 | 38.24 | Upgrade
|
Depreciation & Amortization | 67.53 | 25.87 | 6.4 | 19.62 | 20.09 | 21.41 | Upgrade
|
Other Amortization | 1.16 | 1.24 | 1.36 | 0.11 | 0.25 | 0.29 | Upgrade
|
Loss (Gain) From Sale of Assets | - | - | - | - | - | -0.09 | Upgrade
|
Asset Writedown & Restructuring Costs | - | - | - | 0.14 | 0.11 | 4.52 | Upgrade
|
Loss (Gain) on Equity Investments | 0.17 | - | - | - | - | - | Upgrade
|
Stock-Based Compensation | - | - | - | 0.29 | 0.23 | 0.13 | Upgrade
|
Provision & Write-off of Bad Debts | 0.37 | 0.62 | -0.36 | 0.45 | - | - | Upgrade
|
Other Operating Activities | 4.06 | -1.55 | 6.74 | 1.45 | -0.02 | 1.06 | Upgrade
|
Change in Accounts Receivable | -59.09 | 5.23 | -43.72 | -56.92 | -1.99 | 3.67 | Upgrade
|
Change in Inventory | -41.79 | 9.67 | -5.97 | 13.11 | 15.03 | 3.12 | Upgrade
|
Change in Accounts Payable | 4.54 | -36.25 | 33.64 | -0.63 | -0.54 | 1.41 | Upgrade
|
Change in Unearned Revenue | 8.01 | 0.28 | 6.75 | -3.11 | 0.55 | 3.4 | Upgrade
|
Change in Other Net Operating Assets | -3.77 | 6.81 | 7.71 | 17.5 | 22.44 | -1.6 | Upgrade
|
Operating Cash Flow | 80.79 | 55.98 | 42.58 | 160.76 | 181.86 | 75.56 | Upgrade
|
Operating Cash Flow Growth | - | 31.47% | -73.51% | -11.60% | 140.68% | - | Upgrade
|
Capital Expenditures | -96.72 | -46.24 | - | -9.71 | -1.56 | -0.88 | Upgrade
|
Sale of Property, Plant & Equipment | - | - | - | - | - | 0.18 | Upgrade
|
Cash Acquisitions | 293.22 | 293.22 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | -6.05 | - | -1.52 | -0.09 | -0.15 | - | Upgrade
|
Investment in Securities | -1.39 | - | - | - | - | 5 | Upgrade
|
Other Investing Activities | -37.36 | -28.21 | -1.96 | -1.06 | -0.51 | -0.42 | Upgrade
|
Investing Cash Flow | 151.7 | 218.78 | -3.48 | -10.86 | -2.21 | 3.89 | Upgrade
|
Short-Term Debt Issued | - | - | - | 50 | - | - | Upgrade
|
Total Debt Issued | -1.1 | - | - | 50 | - | - | Upgrade
|
Short-Term Debt Repaid | - | -58.06 | -52.51 | -50 | - | -23.5 | Upgrade
|
Long-Term Debt Repaid | - | -11.25 | -1.38 | -9.88 | -9.29 | -8.76 | Upgrade
|
Total Debt Repaid | -81.71 | -69.31 | -53.9 | -59.88 | -9.29 | -32.26 | Upgrade
|
Net Debt Issued (Repaid) | -82.81 | -69.31 | -53.9 | -9.88 | -9.29 | -32.26 | Upgrade
|
Issuance of Common Stock | 76.5 | 76.5 | 70 | 4.2 | 57.15 | - | Upgrade
|
Repurchase of Common Stock | - | - | -15 | - | - | - | Upgrade
|
Common Dividends Paid | -87.21 | -42.65 | -6.44 | -92.73 | - | - | Upgrade
|
Other Financing Activities | - | - | - | - | 2.45 | - | Upgrade
|
Financing Cash Flow | -93.52 | -35.46 | -5.33 | -98.4 | 50.31 | -32.26 | Upgrade
|
Foreign Exchange Rate Adjustments | -0.52 | -0.68 | - | -0.4 | 0.03 | 0.09 | Upgrade
|
Net Cash Flow | 138.44 | 238.62 | 33.77 | 51.1 | 230 | 47.28 | Upgrade
|
Free Cash Flow | -15.93 | 9.75 | 42.58 | 151.05 | 180.3 | 74.68 | Upgrade
|
Free Cash Flow Growth | - | -77.11% | -71.81% | -16.22% | 141.43% | - | Upgrade
|
Free Cash Flow Margin | -1.96% | 1.71% | 10.01% | 39.71% | 57.33% | 43.37% | Upgrade
|
Free Cash Flow Per Share | -0.32 | 0.33 | 2.14 | 4.47 | 5.65 | 2.25 | Upgrade
|
Cash Interest Paid | 4.09 | 2.09 | 1.32 | 0.09 | 0.2 | 0.64 | Upgrade
|
Cash Income Tax Paid | 15.09 | 11.76 | 2.88 | - | - | 1.9 | Upgrade
|
Levered Free Cash Flow | -203.18 | -76.39 | -43.77 | 85.6 | 132.9 | 61.02 | Upgrade
|
Unlevered Free Cash Flow | -200.62 | -75.08 | -43.05 | 85.66 | 133.03 | 61.42 | Upgrade
|
Change in Net Working Capital | 239.13 | 87.29 | 73.8 | 29.12 | -35.5 | -14.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.